ARTICLE | Clinical News
ATIR regulatory update
May 25, 2015 7:00 AM UTC
EMA classified Kiadis’ ATIR as an advanced therapy medicinal product (ATMP). ATIR is in Phase II testing to reduce transplant-related mortality following hematopoietic stem cell transplant (HSCT) in p...